• 1. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 2. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 3. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847
• 4. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 5. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207

Introduction to (6-Chloro-5-methoxy-pyridin-2-yl)methanol (CAS No: 1227602-31-4)

(6-Chloro-5-methoxy-pyridin-2-yl)methanol, with the CAS number 1227602-31-4, is a significant compound in the realm of chemical and pharmaceutical research. This heterocyclic alcohol has garnered attention due to its versatile structural properties and potential applications in medicinal chemistry. The compound features a pyridine core substituted with a chloro group at the 6-position and a methoxy group at the 5-position, along with a hydroxymethyl group at the 2-position. Such a configuration makes it a valuable scaffold for the development of novel bioactive molecules.

The< strong>pyridine ring is a fundamental structural motif in many pharmacologically active agents, contributing to their binding affinity and metabolic stability. The presence of the< strong>chloro substituent enhances electrophilicity, making it susceptible to nucleophilic substitution reactions, which is pivotal for further functionalization. Conversely, the< strong>methoxy group introduces electron-donating properties, influencing electronic distribution across the molecule and potentially modulating its interactions with biological targets.

In recent years, there has been a surge in research focused on developing small molecules that can modulate neurological pathways. Pyridine derivatives have shown promise in this area, particularly in the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's. The structural features of (6-Chloro-5-methoxy-pyridin-2-yl)methanol make it an attractive candidate for further investigation as a potential lead compound. Its ability to engage with various biological receptors and enzymes suggests that it could be optimized into a therapeutic agent with significant clinical benefits.

The< strong>hydroxymethyl group at the 2-position of the pyridine ring provides a site for further derivatization, allowing chemists to explore diverse chemical space. This flexibility is crucial for medicinal chemists who aim to fine-tune pharmacokinetic and pharmacodynamic properties. For instance, introducing additional functional groups such as amides or esters could alter solubility, bioavailability, and target specificity. Such modifications are essential for advancing a compound from an initial hit to a viable drug candidate.

Recent advancements in computational chemistry have enabled more efficient screening of potential drug candidates. Virtual screening techniques, combined with molecular docking studies, have been instrumental in identifying promising scaffolds like (6-Chloro-5-methoxy-pyridin-2-yl)methanol. These methods allow researchers to predict binding affinities and interactions with biological targets before conducting expensive wet-lab experiments. This approach has significantly accelerated the drug discovery process, making it possible to identify lead compounds much faster than traditional methods.

The< strong>CAS number 1227602-31-4 provides a unique identifier for this compound, ensuring consistency in scientific literature and patent filings. This standardized nomenclature is critical for regulatory purposes and for facilitating communication among researchers worldwide. As such, compounds like (6-Chloro-5-methoxy-pyridin-2-yl)methanol are often cited in databases and publications related to medicinal chemistry and pharmacology.

In conclusion, (6-Chloro-5-methoxy-pyridin-2-yl)methanol represents a compelling example of how structural diversity can be leveraged to develop novel therapeutic agents. Its unique combination of substituents makes it a versatile scaffold for further chemical exploration. With ongoing research focused on neurological disorders and other therapeutic areas, this compound holds considerable promise as a precursor to future drugs. The integration of computational methods into drug discovery continues to enhance our ability to rapidly identify and optimize such promising candidates.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)